EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats

Carlos Núñez-de la Calle, Lluna Careaga, Stefanie Malan-Müller, Álvaro Del Río-García, Yaiza Trueba, Leticia Gil de Biedma-Elduayen, Nuria Morales-Puerto, Rebeca Vidal, Åsa Wiman, Sophie Erhardt, María Dolores Gutiérrez-López, Esther O'Shea and 1 more

British Journal of Pharmacology · 2026-09 · 183 (18) · 5458-5475

DOI: 10.1111/bph.70549 ↗

At a glance

Journal article in British Journal of Pharmacology, published online on 2026-06-23. Written by Carlos Núñez-de la Calle and 12 co-authors. Institution: Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense, Madrid, Spain. Major MEDLINE topics: Kynurenine 3-Monooxygenase, Sucrose, Fentanyl, Behavior, Animal. 91 references. The full text is freely available (open access, CC BY 4.0). Funded by: Swedish Brain Foundation, Ministerio de Ciencia e Innovación, Swedish Research Council.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background and Purpose Opioid use disorder, particularly involving fentanyl, poses major challenges due to high relapse rates and limited effectiveness of pharmacotherapies. The kynurenine pathway has emerged as a target for addiction treatment through its modulation of glutamatergic and dopaminergic neurotransmission. This study investigates the effects of kynurenine 3‐monooxygenase (KMO) inhibition on fentanyl self‐administration in rats. Experimental Approach Adult male rats received the KMO inhibitor, Ro 61‐8048 during fentanyl self‐administration. Responding was assessed across acquisition, maintenance, extinction and reinstatement. The involvement of nicotinic acetylcholine receptor α7 subunit ( α 7nAChR) was investigated using the positive allosteric modulator PNU‐120596. Sucrose self‐administration, locomotor activity and rotarod performance were also evaluated. Kynurenine pathway metabolites were quantified in plasma and nucleus accumbens using ultra‐performance liquid chromatography‐mass spectrometry. Key Results Ro 61‐8048 reduced fentanyl intake and active lever responding across all addiction phases. These effects were associated with increased kynurenic acid (KYNA) levels and altered kynurenine pathway metabolite profiles. PNU‐120596 did not prevent Ro 61‐8048 effects, indicating an α 7nAChR‐independent mechanism. Although Ro 61‐8048 reduced sucrose self‐administration and spontaneous locomotor activity, it did not affect rotarod performance, progressive ratio breakpoints nor did it produce aversive behaviour suggesting that KMO inhibition modulates the reinforcing strength of both drug and natural rewards, rather than inducing general behavioural suppression. Conclusion and Implications KMO inhibition with Ro 61‐8048 robustly attenuates fentanyl‐directed behaviour and affects kynurenine pathway metabolism beyond a shift towards KYNA production. These findings support KMO inhibition as a potential therapeutic strategy for opioid use disorder and warrant further investigation into its underlying mechanisms and translational potential.

Subjects

MeSH terms (MEDLINE)

Kynurenine 3-MonooxygenaseSucroseFentanylBehavior, AnimalOpioid-Related DisordersEnzyme InhibitorsAnimalsMaleRatsSelf AdministrationRecurrenceKynurenineMotor ActivityKynurenic AcidRats, Sprague-DawleySulfonamidesThiazoles

Author keywords

fentanylkynurenine monooxygenasekynurenine pathwayneuropharmacologyopioid‐related disorderspsychopharmacology

Substances

Kynurenine 3-MonooxygenaseRo 61-8048SucroseFentanylEnzyme InhibitorsKynurenineKynurenic AcidSulfonamidesThiazoles

Authors and institutions

  • Departamento de Farmacología y Toxicología, Facultad de Medicina, Universidad Complutense, Madrid, Spain.
  • Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain.
  • Red de Investigación en Atención Primaria en Adicciones (RIAPAd), ISCIII, Madrid, Spain.
  • Instituto Universitario de Investigación en Neuroquímica (IUIN), Facultad de Medicina, Universidad Complutense, Madrid, Spain.
  • Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), ISCIII, Madrid, Spain.
  • Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Funding

  • Swedish Brain Foundation
  • Ministerio de Ciencia e Innovación
  • Swedish Research Council
  • Ministerio de Sanidad
  • Instituto de Salud Carlos III
  • Vetenskapsrådet
  • Ministerio de Sanidad, Servicios Sociales e Igualdad

Cite

APA

Núñez-de la Calle, C., Careaga, L., Malan-Müller, S., Del Río-García, Á., Trueba, Y., Gil de Biedma-Elduayen, L., Morales-Puerto, N., Vidal, R., Wiman, Å., Erhardt, S., Gutiérrez-López, M. D., O'Shea, E., & Colado, M. I. (2026). Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats. British Journal of Pharmacology, 183(18), 5458-5475. https://doi.org/10.1111/bph.70549

Vancouver

Núñez-de la Calle C, Careaga L, Malan-Müller S, Del Río-García Á, Trueba Y, Gil de Biedma-Elduayen L, et al. Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats. British Journal of Pharmacology. 2026;183(18):5458-5475. doi:10.1111/bph.70549

BibTeX
@article{NezdelaCalle2026,
  author = {Núñez-de la Calle, Carlos and Careaga, Lluna and Malan-Müller, Stefanie and Del Río-García, Álvaro and Trueba, Yaiza and Gil de Biedma-Elduayen, Leticia and Morales-Puerto, Nuria and Vidal, Rebeca and Wiman, Åsa and Erhardt, Sophie and Gutiérrez-López, María Dolores and O'Shea, Esther and Colado, María Isabel},
  title = {Inhibition of kynurenine 3‐monooxygenase (KMO) reduces fentanyl and sucrose intake and relapse‐like behaviour in rats},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {18},
  pages = {5458--5475},
  doi = {10.1111/bph.70549}
}
Start for free →